Sexually transmitted infections and contraceptives: Selective issues

Obstetrics and Gynecology Clinics of North America

Volumn 30, Issue 4, 2003, Pages 795-808

  Stuart, Gretchen S ^a   Castaño, Paula M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ESTROGEN; ETHINYLESTRADIOL; LOPINAVIR; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROTEINASE INHIBITOR; RITONAVIR; SPERMICIDAL AGENT; ZIDOVUDINE;

ANEMIA; BACTERIAL VIRULENCE; CHLAMYDIASIS; CLINICAL TRIAL; CONDOM; CONDYLOMA; CONTRACEPTION; ENDOMETRITIS; FEMALE CONTRACEPTIVE DEVICE; GONORRHEA; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INTRAUTERINE CONTRACEPTIVE DEVICE; ORAL CONTRACEPTION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION; WART VIRUS;

EID: 0345731299     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(03)00074-3     Document Type: Review

References (103)

1. Alan Guttmacher Institute. Sexual and reproductive health: women and men. New York: Alan Guttmacher Institute; 2002.
2. Centers for Disease Control and Prevention/National Center for Health Statistics. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Atlanta: Centers for Disease Control and Prevention; 1997.
3. Cates Jr W. Contraception, contraceptive technology, and STDs. In: Holmes KK, Sparling PF, Mardh PA, Lemon SA, Stamm WE, Piot P, et al, editors. Sexually transmitted diseases. New York: McGraw-Hill; 1999. p. 1067-78.
4. Sonnex C. Influence of ovarian hormones on urogenital infection. Sex Transm Infect 1998;74(1):11-9.
5. Brabin L. Hormonal markers of susceptibility to sexually transmitted infections: are we taking them seriously? BMJ 2001;323(7309):394-5.
6. Brabin L. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. AIDS Patient Care STDS 2002;16(5):211-21.
7. Centers for Disease Control and Prevention/National Center for Health Statistics. Chlamydia statistics. Atlanta: Centers for Disease Control; 2003.
8. World Health Organization. UNAIDS: AIDS epidemic update. Geneva: World Health Organization; 2002.
9. Avonts D, Sercu M, Heyerick P, Vandermeeren I, Meheus A, Piot P. Incidence of uncomplicated genital infections in women using oral contraception or an intrauterine device: a prospective study. Sex Transm Dis 1990;17(1):23-9.
10. Blum M, Pery J, Kitai E. The link between contraceptive methods and Chlamydia trachomatis infection. Adv Contracept 1988;4(3):233-9.
11. Richey CM, Macaluso M, Hook EW. Determinants of reinfection with Chlamydia trachomatis. Sex Transm Dis 1999;26(1):4-11.
12. Neu NM, Grumet S, Saiman L, McMahon DJ, Westhoff C. Genital chlamydial disease in an urban, primarily Hispanic, family planning clinic. Sex Transm Dis 1998;25(6):317-21.
13. Park BJ, Stergachis A, Scholes D, Heidrich FE, Holmes KK, Stamm WE. Contraceptive methods and the risk of Chlamydia trachomatis infection in young women. Am J Epidemiol 1995;142(7):771-8.
14. McGregor JA, Hammill HA. Contraception and sexually transmitted diseases: interactions and opportunities. Am J Obstet Gynecol 1993;168(6 Pt 2):2033-41.
15. Goldacre MJ, Loudon N, Watt B, Grant G, Loudon JD, McPherson K, et al. Epidemiology and clinical significance of cervical erosion in women attending a family planning clinic. BMJ 1978;1(6115):748-50.
16. Harrison HR, Costin M, Meder JB, Bownds LM, Sim DA, Lewis M, et al. Cervical Chlamydia trachomatis infection in university women: relationship to history, contraception, ectopy, and cervicitis. Am J Obstet Gynecol 1985;153(3):244-51.
17. Critchlow CW, Wolner-Hanssen P, Eschenbach DA, Kiviat NB, Koutsky LA, Stevens CE, et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. Am J Obstet Gynecol 1995;173(2):534-43.
18. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin Jr HL, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001;185(2):380-5.
19. Cottingham J, Hunter D. Chlamydia trachomatis and oral contraceptive use: a quantitative review. Genitourin Med 1992;68(4):209-16.
20. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 1994;70(3):369-80.
21. Parr MB, Parr EL. Protective immunity against HSV-2 in the mouse vagina. J Reprod Immunol 1997;36(1-2):77-92.
22. Koch ML. The bactericidal action of beta progesterone. Am J Obstet Gynecol 1950;59(1):168-71.
23. Morse SA, Fitzgerald TJ. Effect of progesterone on Neisseria gonorrhoeae. Infect Immunol 1974;10(6):1370-7.
24. Kaushic C, Zhou F, Murdin AD, Wira CR. Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect Immun 2000;68(7):4207-16.
25. Senanayake P, Kramer DG. Contraception and the etiology of pelvic inflammatory disease: new perspectives. Am J Obstet Gynecol 1980;138(7 Pt 2):852-60.
26. Eschenbach DA, Hamisch JP, Holmes KK. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 1977;128(8):838-50.
27. Wolner-Hanssen P, Eschenbach DA, Paavonen J, Kiviat N, Stevens CE, Critchlow C, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990;263(1):54-9.
28. Spinillo A, Gorini G, Piazzi G, Baltaro F, Monaco A, Zara F. The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. Contraception 1996;54(3):163-8.
29. Washington AE, Gove S, Schachter J, Sweet RL. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease: a word of caution about protection. JAMA 1985;253(15):2246-50.
30. Ness RB, Keder LM, Soper DE, Amortegui AJ, Gluck J, Wiesenfeld H, et al. Oral contraception and the recognition of endometritis. Am J Obstet Gynecol 1997;176(3):580-5.
31. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID evaluation and clinical health (PEACH) study. Am J Obstet Gynecol 2001;185(1):121-7.
32. Louv WC, Austin H, Perlman J, Alexander WJ. Oral contraceptive use and the risk of chlamydial and gonococcal infections. Am J Obstet Gynecol 1989;160(2):396-402.
33. Hart G. Factors associated with genital chlamydial and gonococcal infection in females. Genitourin Med 1992;68(4):217-20.
34. Damey PD. Time to pardon the IUD? N Engl J Med 2001;345(8):608-10.
35. Trussell J, Kowal D. The essentials of contraception. In: Hatcher RA, Stewart F, Cates Jr W, Stewart FK, Guest F, Kowal D, editors. Contraceptive technology. New York: Ardent Media, Inc.; 1998. p. 211-76.
36. Shelton JD. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device. Lancet 2001;357(9254):443.
37. Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M, Kokonya D. Complications of use of intrauterine devices among HIV-1-infected women. Lancet 1998;351(9111):1238-41.
38. Faundes A, Telles E, Cristofoletti ML, Faundes D, Castro S, Hardy E. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception 1998;58(2):105-9.
39. Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003;17(2):233-40.
40. Morrison CS, Sekadde-Kigondu C, Miller WC, Weiner DH, Sinei SK. Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception 1999;59(2):97-106.
41. Hodoglugil NN, Aslan D, Bertan M. Intrauterine device use and some issues related to sexually transmitted disease screening and occurrence. Contraception 2000;61(6):359-64.
42. Lazcano Ponce EC, Sloan NL, Winikoff B, Langer A, Coggins C, Heimburger A, et al. The power of information and contraceptive choice in a family planning setting in Mexico. Sex Transm Infect 2000;76(4):277-81.
43. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345(8):561-7.
44. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339(8796):785-8.
45. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356(9234):1013-9.
46. Sinei SK, Schulz KF, Lamptey PR, Grimes DA, Mati JK, Rosenthal SM, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol 1990;97(5):412-9.
47. Coggins C, Sloan NL. Prophylactic antibiotics before insertion of intrauterine devices. Lancet 1998;351(9120):1962-3.
48. Walsh T, Grimes D, Frezieres R, Nelson A, Bernstein L, Coulson A, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices: IUD study group. Lancet 1998;351(9108):1005-8.
49. Bujko M, Sulovic V, Zivanovic V, Lako B, Dotlic R. Effect of progesterone and pregnancy on the replication of herpes simplex virus type 2 in vivo. Clin Exp Obstet Gynecol 1988;15(1-2):34-7.
50. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003;77(8):4558-65.
51. McClelland RS, Wang CC, Richardson BA, Corey L, Ashley RL, Mandaliya K, et al. A prospective study of hormonal contraceptive use and cervical shedding of herpes simplex virus in human immunodeficiency virus type 1-seropositive women. J Infect Dis 2002;185(12):1822-5.
52. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin Jr HL, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001;185(2):380-5.
53. Jacobson DL, Peralta L, Graham NM, Zenilman J. Histologic development of cervical ectopy: relationship to reproductive hormones. Sex Transm Dis 2000;27(5):252-8.
54. Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983;2(8356):930-4.
55. Brabin L. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. AIDS Patient Care STDS 2002;16(5):211-21.
56. Alan Guttmacher Institute. Contraceptive use. New York: Alan Guttmacher Institute; 1998.
57. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999;31(6):272-9.
58. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;(1):CD003255.
59. Saracco A, Musicco M, Nicolosi A, Angarano G, Arici C, Gavazzeni G, et al. Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men. J Acquir Immune Defic Syndr 1993;6(5):497-502.
60. Cates Jr W, Steiner MJ. Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach? Sex Transm Dis 2002;29(3):168-74.
61. Macaluso M, Artz L, Kelaghan J, Austin H, Fleenor M, Hook III EW. Prospective study of barrier contraception for the prevention of sexually transmitted diseases: study design and general characteristics of the study group. Sex Transm Dis 1999;26(3):127-36.
62. Macaluso M, Cheng H, Akers R. Birth control method choice and use of barrier methods for sexually transmitted disease prevention among low-income African-American women. Contraception 2000;62(1):5-13.
63. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285(24):3100-6.
64. Faundes A, Elias C, Coggins C. Spermicides and barrier contraception. Curr Opin Obstet Gynecol 1994;6(6):552-8.
65. Coetzee N, Blanchard K, Ellertson C, Hoosen AA, Friedland B. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. AIDS 2001;15(14):1837-42.
66. Darroch JE, Frost JJ. Women's interest in vaginal microbicides. Fam Plann Perspect 1999;31(1):16-23.
67. Silicone rubber Femcap proves desirable to women. Contracept Technol Update 1993;14(5):78-80.
68. Mauck C, Callahan M, Weiner DH, Dominik R. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm: the FemCap investigators' group. Contraception 1999;60(2):71-80.
69. Shihata AA. The FemCap: a new contraceptive choice. Eur J Contracept Reprod Health Care 1998;3(3):160-6.
70. Gallo MF, Grimes DA, Schulz KF. Cervical cap versus diaphragm for contraception. Cochrane Database Syst Rev 2002;(4):CD003551.
71. Stratton P, Alexander NJ. Prevention of sexually transmitted infections: physical and chemical barrier methods. Infect Dis Clin North Am 1993;7(4):841-59.
72. Trussell J, Sturgen K, Strickler J, Dominik R. Comparative contraceptive efficacy of the female condom and other barrier methods. Fam Plann Perspect 1994;26(2):66-72.
73. Elias CJ, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996;10(Suppl 3):S43-51.
74. Pauwels R, De Clercq E. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11(3):211-21.
75. Nonoxynol-9 spermicide contraception use: United States, 1999. MMWR Morb Mortal Wkly Rep 2002;51(18):389-92.
76. World Health Organization. N-9 ineffective in preventing HIV infection. Geneva: World Health Organization; 2002.
77. International Working Group on Vaginal Microbicides. Recommendations for the development of vaginal microbicides. AIDS 1996;10(8):1-6.
78. McCormack S. Vaginal microbicides. Curr Opin Infect Dis 2002;15(1):57-62.
79. The Population Council. The case for microbicides: a global priority. New York: Population Council; June 11, 2003.
80. Mostad SB, Overbaugh J, DeVange DM, Welch MJ, Chohan B, Mandaliya K, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997;350(9082):922-7.
81. Plourde PJ, Plummer FA, Pepin J, Agoki E, Moss G, Ombette J, et al. Human immunodeficiency virus type 1 infection in women attending a sexually transmitted diseases clinic in Kenya. J Infect Dis 1992;166(1):86-92.
82. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991;163(2):233-9.
83. Simonsen JN, Plummer FA, Ngugi EN, Black C, Kreiss JK, Gakinya MN, et al. HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS 1990;4(2):139-44.
84. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 2000;181(1): 58-63.
85. Martin Jr HL, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998;178(4):1053-9.
86. Clemetson DB, Moss GB, Willerford DM, Hensel M, Emonyi W, Holmes KK, et al. Detection of HIV DNA in cervical and vaginal secretions: prevalence and correlates among women in Nairobi, Kenya. JAMA 1993;269(22):2860-4.
87. Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003;17(2):233-40.
88. Mati JK, Hunter DJ, Maggwa BN, Tukei PM. Contraceptive use and the risk of HIV infection in Nairobi, Kenya. Int J Gynaecol Obstet 1995;48(1):61-7.
89. Stephenson JM. Systematic review of hormonal contraception and risk of HIV transmission: when to resist meta-analysis. AIDS 1998;12(6):545-53.
90. Smith PF, DiCenzo R, Morse GD. Clinical phannacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001;40(12):893-905.
91. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Phannacokinet 2003;42(3):223-82.
92. US Department of Health and Human Services, Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services; February 3, 2002.
93. Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003;17(2):233-40.
94. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine(azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol 1991;32(1):17-21.
95. nd edition. Geneva: World Health Organization; 2002.
96. Lazzarin A, Saracco A, Musicco M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus: risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1991;151(12):2411-6.
97. Kapiga SH, Shao JF, Lwihula GK, Hunter DJ. Risk factors for HIV infection among women in Dar-es-Salaam, Tanzania. J Acquir Immune Defic Syndr 1994;7(3):301-9.
98. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? Br J Obstet Gynaecol 2001;108(8):784-90.
99. Richardson BA, Morrison CS, Sekadde-Kigondu C, Sinei SK, Overbaugh J, Panteleeff DD, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 1999;13(15):2091-7.
100. Cates Jr W. Use of contraception by HIV-infected women. IPPF Med Bull 2003;35:1.
101. Cooling H. Successful use of levonorgestrel intrauterine system in a HIV positive woman. Br J Fam Plann 1999;25(1):25-6.
102. Santelli JS, Davis M, Celentano DD, Crump AD, Burwell LG. Combined use of condoms with other contraceptive methods among inner-city Baltimore women. Fam Plann Perspect 1995;27(2):74-8.
103. Diaz T, Schable B, Chu SY. Relationship between use of condoms and other forms of contraception among human immunodeficiency virus-infected women: supplement to HIV and AIDS surveillance project group. Obstet Gynecol 1995;86(2):277-82.